64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention

Key Takeaways Explain This Topic AI

The USPSTF recommends universal screening for unhealthy alcohol use in all adults aged ≥18 years using validated instruments: AUDIT-C (hazardous threshold: score ≥4 in men, ≥3 in women) or the Single-Question Alcohol Screen (≥5 drinks in a day for men, ≥4 for women).

DSM-5 Alcohol Use Disorder (AUD) severity is stratified by 11 criteria into Mild (2-3 criteria), Moderate (4-5 criteria), and Severe (≥6 criteria) across impaired control, social impairment, risky use, and pharmacological adaptations.

Acute alcohol withdrawal is managed using the CIWA-Ar protocol; scores ≥8-10 trigger symptom-triggered benzodiazepine administration, utilizing lorazepam or oxazepam in patients with hepatic impairment or cirrhosis due to direct glucuronidation without active CYP metabolites.

Delirium Tremens (DTs) emerges 48-96 hours post-cessation with profound hyperadrenergic instability and fluctuating delirium carrying a 5% mortality; high-dose parenteral thiamine must always precede intravenous glucose to avoid precipitating acute Wernicke encephalopathy.

First-line relapse prevention pharmacotherapies include oral naltrexone (50 mg daily) or extended-release injectable naltrexone (380 mg IM monthly; mu-opioid antagonist reducing heavy drinking; safe to start while drinking; strictly contraindicated with active opioid use or acute liver failure) and acamprosate (666 mg TID; NMDA/GABA modulator; maintains abstinence; safe in hepatic cirrhosis; strictly contraindicated if CrCl <30 mL/min).

Last updated: September 2026

Epidemiology, Screening & The Spectrum of Alcohol Use

Alcohol misuse represents the third leading preventable cause of death in the United States, responsible for over 140,000 deaths annually and contributing substantially to cardiovascular disease, liver cirrhosis, pancreatitis, neurocognitive decline, trauma, and oncologic malignancies (particularly head and neck, esophageal, colorectal, and breast cancers).

Universal Screening Guidelines

The United States Preventive Services Task Force (USPSTF) assigns a Grade B recommendation to screening for unhealthy alcohol use in all primary care adults aged 18 years and older, including pregnant individuals, followed by providing those engaged in risky drinking with brief behavioral counseling interventions.

Validated primary care screening modalities include:

AUDIT-C (Alcohol Use Disorders Identification Test - Consumption) : A 3-item self-report questionnaire assessing drinking frequency, typical quantity, and frequency of heavy episodic bingeing. Each item is scored 0 to 4 points (total 0–12 points):

Positive Screen for Hazardous Drinking : Score ≥ 4 \ge 4 ≥ 4 in adult men; score ≥ 3 \ge 3 ≥ 3 in adult women and all adults aged ≥ 65 \ge 65 ≥ 65 years.

Offers high diagnostic sensitivity (86%) and specificity (89%) for detecting the spectrum of unhealthy alcohol use.

Single-Question Alcohol Screen (National Institute on Alcohol Abuse and Alcoholism [NIAAA]) :

Prompt : "How many times in the past year have you had 5 (for men) or 4 (for women) or more drinks in a single day?"

Positive Screen : Any response ≥ 1 \ge 1 ≥ 1 episode is considered positive (sensitivity and specificity > 80 % >80\% > 80% ) and warrants a comprehensive clinical evaluation.

Full 10-Item AUDIT : Developed by the World Health Organization (WHO), evaluating consumption, dependence symptoms, and alcohol-related harms (scores 8–15 indicate hazardous/harmful use; ≥ 16 \ge 16 ≥ 16 indicates severe dependence).

CAGE Questionnaire : An older 4-item mnemonic (Cut down, Annoyed, Guilty, Eye-opener). While historical, the USPSTF notes CAGE lacks sensitivity for identifying the full continuum of hazardous drinking because it detects primarily late-stage, severe dependence; AUDIT-C is preferred.

Standard Drink Quantitation & Consumption Thresholds

Accurate clinical assessment requires quantitating alcohol consumption in terms of standard drink equivalents . In the United States, one standard drink is defined as containing 14.0 grams (0.6 fluid ounces) of pure ethanol :

12 fluid ounces of regular beer (approximately 5 % 5\% 5% alcohol by volume [ABV]).

5 fluid ounces of table wine (approximately 12 % 12\% 12% ABV).

1.5 fluid ounces (one shot) of 80-proof distilled spirits (approximately 40 % 40\% 40% ABV; e.g., vodka, gin, whiskey, rum). DEFINITIONS OF DRINKING PATTERNS (NIAAA / CDC)

Pattern Operational Definition (Standard Drinks) Clinical Significance

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Moderate Drinking • Men: ≤ 2 drinks per day Upper limit of dietary guidelines;

Women: ≤ 1 drink per day no health benefits in young adults.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
Binge Drinking • Men: ≥ 5 drinks on a single occasion (~2 hours) Brings Blood Alcohol Concentration
(Episodic Heavy) • Women: ≥ 4 drinks on a single occasion (~2 hours) (BAC) to ≥ 0.08 g/dL (17.4 mmol/L);

drives acute trauma and arrhythmias.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
Heavy Drinking • Men: ≥ 15 drinks per week Significantly increases risk of
(Chronic Excessive) • Women: ≥ 8 drinks per week alcoholic liver disease, cardiomyopathy,

(or any binge drinking on ≥ 5 days in a month) hypertension, and malignancy.

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

Diagnostic Criteria: DSM-5 Alcohol Use Disorder

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), integrates the prior separate categories of "alcohol abuse" and "alcohol dependence" into a single diagnostic continuum termed Alcohol Use Disorder (AUD) . A problematic pattern of alcohol use leading to clinically significant impairment or distress is defined by the presence of at least 2 of 11 criteria occurring within a 12-month period across four behavioral domains: THE 11 DSM-5 CRITERIA FOR ALCOHOL USE DISORDER

Domain DSM-5 Criterion Description

Impaired Control 1. Alcohol consumed in larger amounts or over a longer period than intended.

2. Persistent desire or unsuccessful efforts to cut down or control alcohol use.

3. Great deal of time spent in activities necessary to obtain, use, or recover.

4. Craving, or a strong desire or urge to use alcohol.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
Social Impairment 5. Recurrent alcohol use resulting in failure to fulfill major role obligations

at work, school, or home.

6. Continued alcohol use despite persistent or recurrent social/interpersonal problems.

7. Important social, occupational, or recreational activities given up or reduced.

───────────────────────────────────────────────────────────────────────────────────────────────────────────

Risky Use 8. Recurrent alcohol use in situations in which it is physically hazardous (e.g., driving).

9. Continued alcohol use despite knowledge of having a persistent or recurrent physical

or psychological problem caused or exacerbated by alcohol.

───────────────────────────────────────────────────────────────────────────────────────────────────────────

Pharmacological 10. Tolerance, defined by either:

a) Need for markedly increased amounts of alcohol to achieve intoxication/desired effect.

b) Markedly diminished effect with continued use of the same amount of alcohol.

11. Withdrawal, manifested by either:

a) Characteristic withdrawal syndrome for alcohol.

b) Alcohol (or a closely related substance, such as a benzodiazepine) is taken to

relieve or avoid withdrawal symptoms.

Severity Stratification

Severity is categorized according to the absolute number of diagnostic criteria met:

Mild AUD : 2 to 3 criteria present.

Moderate AUD : 4 to 5 criteria present.

Severe AUD : ≥ 6 \ge 6 ≥ 6 criteria present.

Diagnostic Nuance : Neither tolerance nor withdrawal is strictly required to establish a diagnosis of AUD if sufficient psychosocial and behavioral criteria are met. Furthermore, tolerance and withdrawal developed during medically supervised treatment with prescription medications (e.g., benzodiazepines) do not count toward criteria 10 and 11.

Neurobiology & Acute Alcohol Withdrawal Syndrome
Neurochemical Pathophysiology

Ethanol is a central nervous system depressant with dual primary molecular targets:

GABA A \text{GABA}_\text{A} GABA A Receptor Potentiation : Ethanol acts as a positive allosteric modulator at inhibitory gamma-aminobutyric acid type A ( GABA A \text{GABA}_\text{A} GABA A ) receptors, increasing chloride ion influx, hyperpolarizing neuronal membranes, and dampening CNS excitability.

NMDA Receptor Inhibition : Ethanol non-competitively antagonizes excitatory N-methyl-D-aspartate (NMDA) glutamate receptors, suppressing excitatory glutamatergic neurotransmission.

With chronic, heavy ethanol exposure, homeostatic neuroadaptation occurs:

Downregulation and desensitization of GABA A \text{GABA}_\text{A} GABA A receptors .

Upregulation of NMDA glutamate receptors and voltage-gated L-type calcium channels .

When ethanol is abruptly removed or rapidly cleared from the circulation, this adaptive neurochemical balance collapses: the loss of inhibitory GABAergic tone unmasks massive, unopposed excitatory glutamatergic neurotransmission and central noradrenergic hyperactivity (excess locus coeruleus firing). This hyperadrenergic state drives the clinical manifestations of acute alcohol withdrawal syndrome (AWS) . TIMELINE OF ACUTE ALCOHOL WITHDRAWAL MANIFESTATIONS

Hours Post-Cessation Clinical Manifestations Features & Differential Clues

6 to 12 Hours Minor Withdrawal Syndrome Tremor, anxiety, diaphoresis, insomnia,
Autonomic hyperactivity tachycardia (HR > 100), hypertension,

Gastrointestinal distress nausea, vomiting; SENSORIUM IS INTACT.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
12 to 48 Hours Alcoholic Hallucinosis Auditory, visual, or tactile perceptions;
(Occurs in ~10-25% of severe AWS) PATIENT REMAINS FULLY ORIENTED with clear

sensorium and intact insight.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
24 to 48 Hours Withdrawal Seizures Generalized tonic-clonic, brief, single
("Rum Fits") or short burst; normal post-ictal EEG;

treat with IV benzos (NOT phenytoin!).

───────────────────────────────────────────────────────────────────────────────────────────────────────────
48 to 96 Hours DELIRIUM TREMENS (DTs) Profound fluctuating delirium, global confusion,
(Peak at 72-96h) • Severe autonomic instability extreme agitation, visual/tactile hallucinations,
Hyperpyrexia, drenching sweats fever (> 38.3°C), marked tachycardia (> 120),

• Life-threatening medical crisis hypertension. MORTALITY RATE UP TO 5%.

Delirium Tremens vs. Alcoholic Hallucinosis

A cardinal board-exam distinction is differentiating Alcoholic Hallucinosis from Delirium Tremens :

Alcoholic Hallucinosis develops within 12–24 hours, features vivid sensory illusions (e.g., hearing voices, seeing insects), but the patient's cognitive sensorium remains entirely clear (oriented to person, place, and time with normal vital signs or mild tachycardia).

Delirium Tremens (DTs) emerges later (48–96 hours) and is defined by clouding of consciousness, disorientation, severe fluctuating delirium, and violent autonomic storm (hyperthermia, diaphoresis, malignant hypertension, marked tachycardia). DTs represents an intensive care medical emergency requiring high-dose intravenous benzodiazepines, fluid resuscitation, electrolyte repletion, and hemodynamic monitoring.

Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar)

The CIWA-Ar is a validated 10-item instrument used to quantify withdrawal severity and titrate pharmacotherapy:

Scores range from 0 to 67 points.

Evaluates: Nausea/vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache/fullness in head, and orientation/clouding of sensorium.

Score < 8 < 8 < 8 : Mild withdrawal; generally managed with supportive care without medications.

Score 8 to 14 : Moderate withdrawal; warrants initiation of pharmacotherapy.

Score ≥ 15 \ge 15 ≥ 15 : Severe withdrawal; high risk for seizures and progression to DTs; mandates aggressive pharmacotherapy.

Inpatient Pharmacotherapy: Symptom-Triggered Benzodiazepine Protocols

Symptom-triggered therapy (administering medication only when CIWA-Ar ≥ 8 − 10 \ge 8-10 ≥ 8 − 10 ) is proven superior to fixed-schedule dosing, achieving shorter treatment duration, lower cumulative benzodiazepine exposure, and lower rates of oversedation.

Benzodiazepine Selection Based on Hepatic Function :

Intact Hepatic Function : Long-acting agents such as diazepam (5–10 mg IV/PO) or chlordiazepoxide (25–50 mg PO) provide smooth, sustained self-tapering protection against breakthrough seizures and delirium due to their long elimination half-lives and active metabolites (e.g., desmethyldiazepam).

Hepatic Impairment / Advanced Cirrhosis / Acute Hepatitis : Long-acting agents undergo hepatic cytochrome P450 oxidation (Phase I metabolism), which is markedly impaired in cirrhosis, leading to toxic drug accumulation, profound oversedation, respiratory depression, and precipitation of hepatic encephalopathy.

The Clinical Rule : Use the "LOT" drugs — Lorazepam , Oxazepam , and Temazepam .

These agents bypass Phase I oxidation and undergo direct Phase II glucuronidation , which is preserved even in end-stage liver disease. They possess no active metabolites.

Preferred Regimen in Liver Disease : Lorazepam 1 to 2 mg PO/IV or Oxazepam 15 to 30 mg PO every 1 to 2 hours titrated to CIWA-Ar < 8 − 10 <8-10 < 8 − 10 .

Wernicke-Korsakoff Syndrome & The Thiamine Mandate

Chronic alcohol misuse impairs gastrointestinal thiamine (Vitamin B 1 B_1 B 1 ) absorption, decreases hepatic thiamine storage, and reduces cellular utilization via thiamine pyrophosphokinase inhibition. Thiamine is an obligate cofactor for key carbohydrate metabolic enzymes: pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase.

Wernicke Encephalopathy : Acute, reversible neuropsychiatric syndrome characterized by the classic clinical triad:

Encephalopathy / Acute Confusion (82% of cases): Profound disorientation, inattention, apathy.

Oculomotor Dysfunction (29% of cases): Bilateral abducens (CN VI) nerve palsy, horizontal/vertical nystagmus, conjugate gaze palsy.

Gait Ataxia (23% of cases): Vestibular dysfunction and cerebellar vermis atrophy producing a broad-based, unsteady gait.

Note : Less than one-third of patients exhibit the complete triad; any unexplained confusion, ataxia, or ophthalmoplegia in a malnourished or alcohol-dependent patient mandates presumptive treatment.

Korsakoff Syndrome : Chronic, irreversible neurocognitive sequela resulting from structural necrosis of the mammillary bodies and dorsomedial thalamic nuclei . Characterized by severe anterograde and retrograde amnesia with confabulation (fabrication of memories without conscious intent to deceive) and lack of insight.

[!CRITICAL] Parenteral Thiamine Before Glucose Always administer high-dose parenteral thiamine ( 500 mg IV TID for 2 to 3 days , followed by 250 mg IV daily) BEFORE or SIMULTANEOUSLY WITH intravenous glucose or dextrose-containing fluids. Administering glucose to a thiamine-deficient patient accelerates aerobic glycolysis, rapidly consuming residual thiamine stores and precipitating acute, fatal Wernicke encephalopathy and brainstem herniation.

Evidence-Based Pharmacotherapy for AUD Maintenance & Relapse Prevention

Following successful acute detoxification, pharmacotherapy should be offered to all patients with moderate-to-severe AUD to promote abstinence or reduce heavy drinking days. The American Psychiatric Association (APA) and Substance Abuse and Mental Health Services Administration (SAMHSA) recommend naltrexone or acamprosate as first-line agents. COMPARISON OF PHARMACOTHERAPIES FOR ALCOHOL USE DISORDER

Medication Mechanism of Action Dosing & Formulation Key Indications & Advantages Strict Contraindications & Risks

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Naltrexone Mu-opioid receptor • Oral: 50 mg PO daily First-line; dampens euphoria • ACTIVE OPIOID USE / DEPENDENCE

(Oral: Revia; antagonist; blocks • IM (Vivitrol): 380 mg and craving; reduces heavy (requires 7–14 day washout;

IM: Vivitrol) endogenous β-endorphin gluteal injection every drinking days; CAN BE STARTED precipitates acute withdrawal!)

reward pathways 4 weeks WHILE PATIENT IS STILL DRINKING. • Acute hepatitis or liver failure.

───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Acamprosate NMDA receptor antagonist; • 666 mg PO three times First-line; RESTORES GLUTAMATE/ • SEVERE RENAL IMPAIRMENT

(Campral) GABA-A receptor agonist; daily (two 333 mg GABA BALANCE; superior for (CrCl < 30 mL/min contraindicated;

modulates post-cessation delayed-release tablets MAINTAINING COMPLETE ABSTINENCE; dose-reduce to 333 mg TID if

hyperglutamatergic tone TID) SAFE IN ADVANCED CIRRHOSIS/LIVER. CrCl 30–50 mL/min).

Disulfiram Irreversible aldehyde • 250 to 500 mg PO Aversion / deterrent therapy; • Severe coronary artery disease

(Antabuse) dehydrogenase (ALDH) once daily requires highly motivated • Psychosis; pregnancy
inhibitor; triggers toxic patient or DIRECTLY OBSERVED • Concomitant metronidazole

acetaldehyde buildup DAILY ADMINISTRATION. • Severe baseline hepatic disease.

Gabapentin Voltage-gated calcium • 300 mg TID titrated to Off-label; treats protracted • Dose-dependent sedation

(Neurontin) channel α2-δ ligand; 900–1800 mg/day in withdrawal, insomnia, and • Abuse liability (Schedule V

indirect GABA enhancement divided doses dysphoric craving; SAFE IN LIVER. in some states); renal adjustment.

Topiramate AMPA/kainate antagonist; • 25 mg daily titrated to Off-label; reduces heavy • Cognitive slowing ("Dopamax")

(Topamax) carbonic anhydrase inhibitor; 100–300 mg/day in drinking and craving; promotes • Paresthesias; nephrolithiasis

facilitates GABA release divided doses concomitant weight loss. • Glaucoma; teratogenic (cleft lip).

1. Naltrexone (Revia, Vivitrol)

Mechanism : Naltrexone is a competitive antagonist at mu-opioid receptors. In alcohol consumption, ethanol stimulates the release of endogenous beta-endorphins that bind mu receptors in the ventral tegmental area (VTA), disinhibiting dopamine release in the nucleus accumbens. By blocking mu receptors, naltrexone attenuates the dopaminergic "high" and hedonic reinforcement of alcohol, breaking the positive-reinforcement cycle and reducing heavy drinking days.

Initiation Pearl : Patients do NOT need to be abstinent prior to starting naltrexone. It can be initiated while the patient is still actively drinking to help reduce consumption.

Formulations :

Oral : 50 mg once daily (start at 25 mg daily for 2–3 days to minimize initial gastrointestinal side effects).

Intramuscular Depot (Vivitrol) : 380 mg administered as a deep intramuscular gluteal injection every 4 weeks. Vivitrol bypasses daily oral adherence barriers and provides sustained therapeutic drug levels.

Adverse Effects : Nausea, abdominal pain, headache, dizziness, fatigue, and dose-dependent hepatotoxicity at supra-therapeutic doses.

Strict Contraindications :

Concurrent Opioid Analgesic Therapy or Opioid Use Disorder : Naltrexone will immediately displace full and partial agonists, precipitating severe, acute opioid withdrawal. Patients must be completely opioid-free for at least 7 to 10 days for short-acting opioids and 14 days for buprenorphine or methadone before initiation.

Acute Hepatitis or Acute Hepatic Failure : While stable, mild-to-moderate chronic cirrhosis is not an absolute contraindication, naltrexone should be avoided in acute hepatic necrosis, acute alcoholic hepatitis, or decompensated liver failure with jaundice.

2. Acamprosate (Campral)

Mechanism : Chronic ethanol consumption creates an up-regulated glutamatergic excitatory state. Acamprosate (calcium acetylhomotaurinate) structurally resembles GABA and taurine. It acts as a functional glutamate NMDA receptor antagonist and a modulator of GABA A \text{GABA}_\text{A} GABA A receptors, dampening post-detoxification "hyper-glutamatergic tone" ("putting out the neurochemical fire"). This reduces protracted withdrawal symptoms, restlessness, and negative-reinforcement craving.

Efficacy : Acamprosate is most effective for sustaining complete abstinence in patients who have already achieved detoxification. It does not mitigate the acute reinforcing effects if alcohol is consumed.

Dosing : 666 mg PO three times daily (administered as two 333 mg tablets TID). The frequent TID dosing represents a common barrier to long-term medication adherence.

Elimination & Organ Safety :

Hepatic : Acamprosate is not metabolized by the liver and does not interact with cytochrome P450 enzymes. It is completely safe in patients with severe hepatic disease, non-alcoholic fatty liver disease, and advanced alcoholic cirrhosis.

Renal : Acamprosate is excreted 100% unchanged by the kidneys .

Renal Dosing Guidelines :

CrCl > 50 mL/min \text{CrCl} > 50\text{ mL/min} CrCl > 50 mL/min : Full dose (666 mg TID).

CrCl 30 − 50 mL/min \text{CrCl } 30-50\text{ mL/min} CrCl 30 − 50 mL/min : Dose reduction to 333 mg TID.

CrCl < 30 mL/min \text{CrCl} < 30\text{ mL/min} CrCl < 30 mL/min : STRICTLY CONTRAINDICATED due to dangerous drug accumulation.

3. Disulfiram (Antabuse)

Mechanism : Disulfiram is an irreversible inhibitor of aldehyde dehydrogenase (ALDH) , the enzyme responsible for converting acetaldehyde (a toxic intermediate of ethanol oxidation) into acetate. Ingestion of even minor amounts of alcohol causes blood acetaldehyde levels to surge 5- to 10-fold within 10 to 30 minutes.

The Disulfiram-Ethanol Reaction : Acetaldehyde accumulation induces severe, distressing, and potentially dangerous physiological symptoms: facial flushing, throbbing headache, diaphoresis, nausea, intractable vomiting, tachycardia, palpitations, dyspnea, and hypotension. The reaction lasts 30 to 120 minutes.

Clinical Role & Limitations : Disulfiram acts purely as a psychological deterrent. It does not reduce physiological cravings or modulate reward circuits. Randomized clinical trials show that unmonitored disulfiram is no more effective than placebo due to poor treatment adherence (patients simply stop taking the pill when they plan to drink). It is effective only when administered under direct daily supervision (by a spouse, clinic nurse, or parole officer) in highly motivated patients.

Contraindications : Severe coronary artery disease, congestive heart failure, history of stroke, psychosis, cognitive impairment, pregnancy, and concurrent use of metronidazole (compounds ALDH inhibition, risking acute delirium). Patients must avoid hidden alcohol sources (cough syrups, aftershave lotions, vinegar, mouthwashes).

4. Second-Line & Off-Label Pharmacotherapies

Gabapentin : Administered at doses of 900 to 1800 mg/day in divided doses. By binding the α 2 - δ \alpha_2\text{-}\delta α 2 - δ subunit of voltage-gated calcium channels, gabapentin reduces excitatory neurotransmission. It alleviates protracted subacute withdrawal symptoms: insomnia, anxiety, dysphoria, and craving. Because it undergoes zero hepatic metabolism and is excreted renally, gabapentin is an outstanding option for patients with alcoholic cirrhosis or elevated liver transaminases.

Topiramate : Administered at 100 to 300 mg/day. Facilitates GABA transmission while antagonizing kainate/AMPA glutamate receptors. Reduces heavy drinking and craving. Side effects include psychomotor slowing ("dopamax"), paresthesias, metabolic acidosis, anorexia/weight loss, and nephrolithiasis.

Psychosocial Modalities in Longitudinal Care

Pharmacotherapy demonstrates the highest efficacy when integrated with structured evidence-based psychosocial interventions:

Motivational Interviewing (MI) & The FRAMES Approach :

F eedback on personal risk and current health status.

R esponsibility placed on the patient for personal change.

A dvice to change delivered clearly and nonjudgmentally.

M enu of alternative options and strategies.

E mpathy emphasized throughout the encounter.

S elf-efficacy supported and reinforced.

Cognitive Behavioral Therapy (CBT) : Identifies conditioned internal and external environmental triggers, restructures distorted cognitive patterns surrounding drinking, and develops behavioral coping skills to manage high-risk relapse scenarios.

12-Step Mutual-Aid Fellowships (Alcoholics Anonymous [AA]) : A free, globally accessible, spiritually based, peer-led fellowship providing 24/7 social accountability, sponsorship, and structured behavioral steps toward maintaining continuous sobriety.